Takara Bio Europe announced the launch of Cellartis® MSC EV Wonder™, a defined, xeno-free medium engineered for the scalable production of extracellular vesicles (EVs) from human mesenchymal stem cells (MSCs).

MSC-derived EVs are increasingly recognized as next-generation, cell-free therapeutic candidates, offering regenerative and immunomodulatory benefits without the safety concerns associated with administering intact MSCs. As the field shifts from MSC-based approaches to MSC-EVs, researchers are seeking solutions that deliver both robust yields and reproducible quality at scale.

Cellartis MSC EV Wonder meets this need by enabling up to a nine-fold increase in EV production compared to conventional DMEM while maintaining critical attributes such as canonical CD marker expression, morphology, and RNA profile. The medium’s defined, phenol red–free formulation uses the same basal medium as the Cellartis MSC Xeno-Free Culture System, ensuring a seamless transition from MSC expansion to EV production.

“We developed Cellartis MSC EV Wonder around a chemically defined supplement that eliminates variability and preserves essential MSC-EV features, enabling reproducible results and a smooth transition to GMP manufacturing for clinical applications,” said Clemence Bonhomme, Scientist, Takara Bio Europe.

“Consistent, scalable production of high-quality MSC-EVs has been a bottleneck for the field,” said Tarik Hadi, PhD, Senior Market Strategy Manager at Takara Bio Europe. “With Cellartis MSC EV Wonder, we provide a defined solution that streamlines workflows, safeguards quality, and accelerates the path from discovery to translation.”